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Abstract
Background: Some authors consider that secondary prevention should be conducted for all DM2 patients,
while others suggest that the drug preventive treatment should start or be increased depending on each
patient’s individual CVR, estimated using cardiovascular or coronary risk functions to identify the patients with
a higher CVR. The principal objective of this study was to assess three different cardiovascular risk prediction
models in type 2 diabetes patients.
Methods: Multicentre, cross-sectional descriptive study of 3,041 patients with type 2 diabetes and no history of
cardiovascular disease. The demographic, clinical, analytical, and cardiovascular risk factor variables associated with
type 2 diabetes were analysed. The risk function and probability that a cardiovascular disease could occur were estimated
using three risk engines: REGICOR, UKPDS and ADVANCE. A patient was considered to have a high cardiovascular risk
when REGICOR≥ 10 % or UKPDS≥ 15 % in 10 years or when ADVANCE≥ 8 % in 4 years.
Results: The ADVANCE and UKPDS risk engines identified a higher number of diabetic patients with a high cardiovascular
risk (24.2 % and 22.7 %, respectively) compared to the REGICOR risk engine (10.2 %). The correlation using the REGICOR
risk engine was low compared to UKPDS and ADVANCE (r = 0.288 and r = 0.153, respectively; p < 0.0001). The agreement
values in the allocation of a particular patient to the high risk group was low between the REGICOR engine and the
UKPDS and ADVANCE engines (k = 0.205 and k = 0.123, respectively; p < 0.0001) and acceptable between the ADVANCE
and UKPDS risk engines (k = 0.608).
Conclusions: There are discrepancies between the general population and the type 2 diabetic patient-specific risk
engines. The results of this study indicate the need for a prospective study which validates specific equations for
diabetic patients in the Spanish population, as well as research on new models for cardiovascular risk prediction in
these patients.
Keywords: Type 2 diabetes, Cardiovascular risk prediction, Cardiovascular disease, Risk prediction models, Primary
prediction
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Background
Type 2 diabetes mellitus (DM2) is associated with an in-
creased risk of cardiovascular disease (CVD) [1–3]. This
risk is two to four times higher in DM2 patients than in
non-DM2 patients, independently of the classical cardio-
vascular risk factors (CVRF). Incidence of diabetes is ex-
pected to continue to increase over in the following years
and CVD associated with DM2 will most likely increase as
well [4]. Although diabetes is a risk factor for Coronary
Heart Disease (CHD), whether diabetes alone is a CHD
equivalent in assessing de risk of future CVD events is
controversial. It might be related to multiple causes, such
as those attributable to the different baseline characteris-
tics and different risk profiles of the diabetic patients who
participated in the studies [5, 6]. Type 2 diabetes patients
without other CVRF have a lower risk of CVD, especially
patients with a shorter evolution of the disease and with
fewer metabolic alterations [7]. According to some stud-
ies, the age of diagnosis and the time course of the disease
play a role in its progression, and after 10 to 15 years, the
coronary risk of these diabetic patients is similar to pa-
tients with prior CHD [6, 8, 9].
Some authors consider that secondary prevention should
be conducted for all DM2 patients [10–12], while others
suggest that the drug preventive treatment should start or
be increased depending on each patient’s individual CVR,
especially in countries with limited health resources, and
recommend using cardiovascular or coronary risk func-
tions to identify the patients with a higher CVR who could
benefit more from a treatment scale-up. Moreover, over-
treatment in patients at low risk might be associated with a
higher risk of drug interactions, more significant cost,
inconvenience, and side effect burdens that might engen-
der higher rates of non-adherence [13, 14]. Clearly, these
risk functions should not be applied to DM2 patients with
a previous CVD.
In Spain, several risk strategies are currently used to
estimate CVR. Among these equations, Framingham-
REGICOR (Registre Gironí del Cor) [15] and SCORE
(Systematic Coronary Risk Evaluation) [16] are the most
popular. It has been discussed that the former overesti-
mates and the second underestimates CVR [17]. Other
risk models, such as the UK Prospective Diabetes Study
(UKPDS) [18] and the Action in Diabetes and Vascular
Disease Preterax and Diamicron MR Controlled Evalu-
ation (ADVANCE) [19], have been developed exclu-
sively on a DM2 patient cohort.
The ultimate aim of this study was to compare three
different cardiovascular risk-prediction models in three
diabetic patient-based cohorts to determine the variables
involved in the identification of high risk patients, ac-
cording to the equation used, and to analyse the vari-
ables associated with the discrepancy among the three
risk functions.
Methods
Cross-sectional descriptive study. Patients were selected
from the database of three previous studies of the Net-
work of Diabetes Study Group in Primary Health Care
(redGDPS, for its initials in Spanish), which were: CVRF-
Primary Health Care Diabetes Study Group (GEDAPS);
Study of Immigrant Diabetes in Spain (IDIME) and Preva-
lence of chronic kidney disease in patients with type 2 dia-
betes in Spain (PERCEDIME2). The methodology, design
and results of these studies have been published previously
[20–22]. In the three studies the following methodology
had been used. Health providers were instructed to obtain
a random sample from the medical records of type 2 DM
patients with a follow-up greater than 6 months since
diagnosis. A total sample of five patients multiplied by the
number of basic care units, with a minimum of 30 pa-
tients per centre, was required. A pre-selection of medical
records with an additional 20 % was performed. Data were
collected from paper medical records from 1997 to 2002
and from electronic records in 2007 (FRCV-GEDAPS). A
multicentre, observational, cross-sectional study including
a cohort of 605 diabetic immigrants and 307 native dia-
betics was conducted on patients diagnosed with diabetes
and treated in primary and specialised care in Spain. A
consecutive sampling method had been followed (IDIME).
Finally, a national cross-sectional study was performed in
primary care consults with 1,145 type 2 diabetics. The pa-
tients included both genders and they were over 40 years
old. Moreover, the patients had all of the variables neces-
sary for the study included in their clinical history. The pa-
tients were selected by a convenience sample of the first
three patients with DM2 who came to the consultation
each day for any reason and met the inclusion criteria until
the number of participants per researcher was completed.
The information for each participant was collected in the
period from February to July 2011 (PERCEDIME2).
FRCV-GEDAPS study was approved by the Consell
Assessor de la Diabetes (Advisory Board on Diabetes)
of the Health Departament of Catalunya; IDIME study
was approved by the Clinical Research Ethics Commit-
tee of the IMIM-Hospital del Mar, Barcelona, Spain
(Project number 2008/3176/I) and PERCEDIME2 study
was approved by the Ethical and Clinical Investigation
Committee of the Institut d’Assistència Sanitària (IAS),
Girona, Spain. All participants provided written in-
formed consent.
Analysed variables
The following variables were analysed: age, gender, ethni-
city, years since diabetes diagnosis, %HbA1c, body mass
index (BMI) kg/m [2], waist circumference (WC) in cm;
tobacco consumption (considering a daily consumer of
any amount as a smoker and as an ex-smoker after one
year of abstinence); systolic (SBP) and diastolic blood
Rodriguez-Poncelas et al. BMC Cardiovascular Disorders  (2015) 15:121 Page 2 of 8
pressure (DBP) and pulse pressure (PP) (mmHg), includ-
ing the diagnosis of high blood pressure (3 readings ≥
140/90 mmHg); total cholesterol (mg/dl), HDL choles-
terol (mg/dl), and non-HDL cholesterol (mg/dl), as well
as hypercholesterolemia criteria (2 values ≥ 250 mg/dl);
diabetes mellitus according to the American Diabetes
Association [23], as well as previously diagnosed cases
or being on anti-hyperglycaemic treatment prior to the
study; glomerular filtrate (GF) measure using the MDRD-
4 equation [24] and urine albumin excretion rate accord-
ing to albumin/creatinine ratio (mg/g).
The possibility of presenting a CVD was estimated using
three different risk engines, one of them based on a general
population and on a reduced number of patients with
DM2 (REGICOR) and two on exclusively DM2 populations
(UKPDS and ADVANCE). In the ADVANCE equation, a
correction factor based on the prevalence of atrial fibrilla-
tion in the Spanish population with DM2 was considered.
A patient was considered to have a high risk if the values of
REGICOR ≥ 10 % after 10 years, UKPDS ≥ 15 % after
10 years, and ADVANCE ≥ 8 % after 4 years. Framingham-
REGICOR provided estimates of risk for CHD, and UKPDS
and ADVANCE estimate CHD and stroke (Table 1).
Statistical analysis
The CVR was calculated using the three functions listed.
The ratios were compared using the chi-square test and
the means with the t-Student and ANOVA test or the
corresponding non-parametrical tests if the conditions
were not satisfied (McNemar, Mann–Whitney U and
Kruskal-Wallis). An alpha level of statistical significance
of < 0.05 was used in all cases. The correlation between
the studied engines was analysed with the Pearson’s
correlation coefficient and the Kappa coefficient consid-
ering values over 0.6 as an indicative of good agreement.
For the classification of a patient as high cardiovascular
risk, the variables associated with the disagreement among
the different risk functions were evaluated using general-
ised linear models (GLM) with disagreement (1) or no dis-
agreement (0) as the response variables and a binomial
link (logistic regressions). Due to the heterogeneity of the
cohorts, the same generalised lineal model was applied
separately to each cohort to confirm uniformity in the
results.
All of the analyses were performed using the SPSS
statistical programme version 15.0 and R free software
version 3.0.1.
Results
A total of 3,041 patients (53.8 % male; 60.4 years, standard
deviation 9.7), 35 to 74 years old, both inclusive, without a
previous cardiovascular disease were included. The vari-
ables analysed show significant differences in age, gender,
years of diabetes diagnosed, ethnicity, tobacco consump-
tion, pulse pressure, HbA1c, single or combined use of in-
sulin and the prevalence of diabetic retinopathy (Table 2).
The ADVANCE equation identifies a greater number of
diabetic patients with a high cardiovascular risk (n =737,
24.2 %), while REGICOR classifies the lowest number of
patients with a high risk (n = 312, 10.2 %). The UKPDS
classifies a greater number of DM2 patients with a high
cardiovascular risk than the REGICOR equation, and
similar to the ADVANCE equation (n = 691, 22.7 %).
Table 3 shows the characteristics of the DM2 patients
with a high cardiovascular risk for each equation. In the
ADVANCE equation, the profile of the patients with
high risk are older (68.1 years; SD 5.9), with more years
of evolution of DM2 (11.8; SD 7.1), a smaller number of
smokers, high pulse pressure (63.9 mmHg; SD 12.8),
greater impaired kidney function and retinal alterations,
a higher percentage of patients treated with single or
combined insulin with oral antidiabetics (OA), and a
greater number of patients following an antihyperten-
sive treatment. The UKPDS and ADVANCE equations
show similar results in most of the characteristics of the
high risk patients, except for age, pulse pressure, antihy-
pertensive drug consumption, and impairment of kidney
function. REGICOR classifies as high risk patients a higher
number of male smokers with elevated levels of non-HDL
cholesterol and low levels of HDL cholesterol.
According to the real validity assessment, the correl-
ation and agreement among the different equations were
poor, despite the statistical significance. Only the values
of correlation and agreement between the DM2 patient-
specific equations (ADVANCE and UKPDS) were signifi-
cant (r = 0.752, p < 0.0001 and k = 0.608, p < 0.0001; re-
spectively). The correlation of the REGICOR equation with
Table 1 Variables considered in each cardiovascular risk engine
REGICOR UKPDS ADVANCE
Age × × ×
Age of DM2 diagnosis − × ×
Gender × × ×
Ethnicity − × −
Tobacco × × −
SBP × × *
Total cholesterol × * *
Time of evolution of DM2 − × ×
HbA1c − × ×
Antihypertensive treatment − − ×
Microalbuminuria − − ×
Retinopathy − − ×
Atrial fibrillation − − ×
(×): included variable; (−): variable not included; (*): included variable with
some modifications
DM2 diabetes mellitus type 2, SBP systolic blood pressure
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UKPDS and ADVANCE was low (r = 0.288 and r = 0.153,
respectively; p < 0.0001). The agreement scores when
assigning a specific patient to the high risk group were low
for the REGICOR risk equation compared to UKPDS
and ADVANCE (k = 0.205 and k = 0.123, respectively;
p < 0.0001) but good when comparing the ADVANCE
equation with the UKPDS equation (Table 4).
The sensitivity, specificity and positive and negative pre-
dictive values for UKPDS and ADVANCE equations were
calculated compared to REGICOR equation. For the usual
cut-off points (REGICOR ≥10 %, UKPDS ≥15 %, and
ADVANCE ≥8 %), and considering that REGICOR is the
gold standard as the only validated engine for the Spanish
population, the sensitivity was 0.518 for the UKPDS equa-
tion and 0.394 for the ADVANCE equation; the specificity
was 0.798 and 0.791, respectively. The positive predictive
values were 0.067 and 0.083, respectively, and the negative
predictive values were 0.767 and 0.817, respectively. The
positive likelihood ratios were 2.56 and 1.88, and the nega-
tive likelihood ratios were 0.6 and 0.76, respectively.
The multivariate analysis (Table 5) showed that the time
of evolution of diabetes, specifically for the ADVANCE
equation, the levels of HbA1c, the age of the patient, and
the levels of non-HDL cholesterol were variables associated
with a greater degree of disagreement between REGICOR
equation and the DM2 patient-specific equations when
classifying DM2 patients with a high cardiovascular risk.
Other variables associated with the disagreement between
REGICOR and ADVANCE equations were the presence of
retinopathy, arterial hypertension with drug treatment, to-
bacco consumption, pulse pressure, and urinary albumin
excretion. The same multivariate analysis model for each
separate cohort showed similar results to the global results
of the three cohorts.
Discussion
The results in this study demonstrate that the prevalence
of diabetic patients with high CVR varies according to the
risk equation applied. Each risk equation identifies diabetic
patients with high CVR according to different profiles re-
garding clinical, analytical, and treatment variables. The
ADVANCE equation classifies a higher number of patients
with high CVR, while REGICOR classifies the smallest
number with high CVR. Specifically, ADVANCE classifies
Table 2 Baseline characteristics of the cohorts
All GEDAPS 2007 IDIME PERCEDIME2
n = 3,041 n = 1,774 n = 605 n = 662
Age, years, mean (SD)** 60.4 (9.7) 62.4 (9.0) 53.6 (9.7) 61.3 (8.6)
Gender, men, n (%)* 1638 (53.8) 929 (52.3) 328 (54.2) 384 (58.0)
Years since diabetes diagnosis, mean (SD)** 6.7 (5.5) 6.3 (5.1) 6.6 (6.2) 7.8 (5.8)
Afroamericans/Afrocaribbeans, n (%)** 187 (14.8) 170 (28.1) 17 (2.6)
Tobacco, n (%)** 435 (14.3) 317 (17.8) 4 (0.6) 116 (17.5)
BMI, kg/m2, mean (SD) 30.5 (5.1) 30.5 (5.1) 29.9 (5.8) 30.5 (5.3)
Waist circumference, cm, mean (SD)* 100.9 (15.7) 102.4 (13.2) 99.7 (7.3)
Pulse pressure, mmHg, mean (SD)** 56.9 (13.1) 58.2 (12.9) 55.2 (15.1) 55.6 (11.4)
Glycated haemoglobin, %, mean (SD)** 7.1 (1.6) 6.8 (1.5) 7.6 (1.9) 7.3 (1.3)
HDL, mg/dL, mean (SD)** 48.8 (13.3) 49.8 (13.2) 47.4 (13.9) 47.9 (12.7)
Non-HDL cholesterol** 146.9 (38.3) 148.3 (37.1) 150.9 (43.7) 140.2 (35.1)
UAER, mg/gr, mean (SD)* 29.5 (109.4) 28.4 (88.2) 43.6 (185.4) 24.1 (80.4)
GFR, mil/min/1.73 m2, mean (SD) 75.6 (30.4) 76.29 (32.7) 74.1 (23.9)
Diabetic retinopathy, n (%)** 325 (10.7) 238 (13.4) 52 (8.6) 55 (8.3)
Diabetes therapy, n (%)**
Diet 560 (18.4) 408 (23.0) 63 (10.4) 89 (13.5)
OA 1,063 (34.9) 751 (42.3) 223 (36.9) 89 (13.5)
OA + Insulin 504 (16.5) 150 (8.5) 80 (13.2) 274 (41.4)
Insulin 192 (6.3) 110 (6.2) 48 (7.9) 34 (5.1)
OA combined 722 (23.7) 355 (20.0) 191 (31.6) 176 (26.6)
Antihypertensive treatment, n (%)** 1837 (60.4) 1126 (63.5) 270 (44.6) 440 (66.5)
Dyslipidaemia therapy, n (%)** 1417 (46.6) 929 (52.4) 210 (34.8) 410 (61.9)
BMI body mass index, UAER urinary albumin excretion rate, GFR glomerular filtration rate according to MDRD equation, OA oral antidiabetic drug
*p < 0.05
**p <0.005
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14 % more patients than REGICOR as high CVR. In
addition most of the patients classified as high CVR by
REGICOR equation do not match those classified as high
risk by the UKPDS and ADVANCE equations, as indicated
by the low agreement between the three equations. In fact,
it is observed (Table 2) that high risk patients according
REGICOR are smokers and have a more desvaforable lipid
profile compared to patients with high risk according
UKPDS and ADVANCE functions. Many of these pacients
classified as high risk by REGICOR probably not fall into
this category according to the UKPDS and ADVANCE
functions.
A novel methodological approach in study was devel-
oped. A multivariate model was constructed and adjusted
by multiple covariables to determine the disagreement be-
tween REGICOR equation and UKPDS and ADVANCE
equations. In this model, the variables associated with dis-
agreement can be identified to quantify the independent
impact of each variable. In this context, some variables
such as the time of evolution of diabetes, should be
evaluated.
The results of the ADVANCE study [19] question the
utility of the Framingham and UKPDS engines due to
their low efficiency in predicting the risk of a CVD in dia-
betic patients. Unlike Framingham and UKPDS studies,
ADVANCE study included participants from different
countries and ethnicities and incorporated new predict-
ive variables that were not featured in the Framingham
and UKPDS equations. The external validation of the
Table 3 Characteristics of high-risk patients according to each risk equation
REGICOR UKPDS ADVANCE
n = 312 n = 691 n = 737
Age, years, mean (SD) 64.1 (7.0) 66 (6.6) 68.1 (5.9)
Gender, men, n (%) 221 (70.8) 469 (67.9) 451 (61.2)
Years since diabetes diagnosis, mean (SD) 7.07 (5.4) 12.9 (6.5) 11.8 (7.1)
Afroamericans/Afrocaribbeans, n (%) 11 (3.5) 9 (1.3) 21 (2.8)
Tobacco, n (%) 118 (37.8) 122 (17.7) 86 (11.7)
BMI, kg/m2, mean (SD) 30.2 (4.7) 29.9 (4.6) 30.1 (4.9)
Waist circumference, cm, mean (SD) 100.2 (19.4) 100.0 (16.7) 101.0 (15.8)
Pulse pressure, mmHg, mean (SD) 59.2 (13.0) 61.8 (13.7) 63.9 (12.8)
Glycated haemoglobin, %, mean (SD) 7.4 (1.6) 7.7 (1.6) 7.4 (1.5)
HDL, mg/dL, mean (SD) 36.5 (8.1) 45.3 (12.0) 48.6 (12.8)
Non-HDL cholesterol 171.0 (42.5) 149.7 (38.4) 140.0 (37.4)
UAER, mg/gr, mean (SD) 37.3 (94.6) 43.5 (161.7) 55.1 (150.5)
GFR, mil/min/1.73 m2, mean (SD) 44 (96) 43 (94) 50 (101)
Diabetic retinopathy, n (%) 22 (7.1) 98 (14.2) 140 (19.0)
Diabetes therapy, n (%)
Diet 57 (18.3) 61 (8.8) 73 (10.0)
OA 99 (31.7) 185 (26.8) 232 (31.7)
OA + Insulin 66 (21.2) 152 (22.0) 143 (19.5)
Insulin 18 (5.8) 66 (9.6) 78 (10.7)
OA combined 70 (22.4) 221 (32.0) 206 (28.1)
Antihypertensive treatment, n (%) 226 (72.4) 491 (71.1) 589 (79.9)
Dyslipidaemia therapy, n (%) 168 (53.8) 375 (54.3) 421 (57.1)
High risk is defined as follows: REGICOR ≥ 10 % at 10 years; UKPDS ≥ 15 % at 10 years
ADVANCE ≥ 8 % at 4 years
BMI body mass index, CBP clinic blood pressure, UAER urinary albumin excretion rate, GFR glomerular filtration rate according to MDRD equation, OA oral
antidiabetic drug
Table 4 Agreement among the different risk engines in the
classification of high risk patients
REGICOR UKPDS ADVANCE n
REGICOR 1 0.205 0.123 312
n = 161 n = 123
UKPDS 0.205 1 0.608 691
n = 161 n = 477
ADVANCE 0.123 0.608 1 737
n = 123 n = 477
n 312 691 737 n = 1740
Index of agreement (kappa). All values are significant, p < 0.0001
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UKPDS engine [25] using a contemporary cohort of
diabetic patients showed that the UKPDS engine has a
moderate discriminative capacity and overestimates the
CVR. Marrugat J et al. [26] observed that the REGICOR-
adapted function’s estimate did not differ from the
observed cumulated incidence. In men and women with
diabetes (16.4 %), the Kaplan-Meier observed overall 5-
year CHD event rate was 4.9 %. The original Framingham
function significantly overestimated the event rate by a
factor > 2.6; the prediction of the Framingham-REGICOR
adapted function did not differ from the observed rate.
Cañón Barroso L et al. [27] observed that the compari-
son between the mean coronary risk estimated by the
original Framingham equation (Framingham-Wilson)
and the calibrated one for the Spanish population
(Framingham-REGICOR) in diabetic patients showed
that Framingham-REGICOR underestimated the actual
coronary risk (11.3 % versus 15.0 %) while
Framingham-Wilson overestimated the risk (27.4 %
versus 15.0 %) and Jimeno Mollet et al. [28] found
that Framingham-REGICOR underestimated the cor-
onary risk at 10 years, 20 % and 40 % for men and
women respectively. European guidelines on diabetes
[29] recommend not to value the risk CVD in
patients with DM with risk scores developed for the
general population. Framingham-REGICOR risk scores
was developed for the general population, and only
16.4 % were diabetic patients, whilst in UKPDS and
ADVANCE all were diabetic patients.
Sha AD et al. [30] observed that type 2 diabetes was
positively associated with peripheral arterial disease
(adjusted HR 2.98 [95 % CI 2.76-3.22]), ischaemic stroke
(1.72 [1.52-1.95]), stable angina (1.62 [1.49-1.77]), heart
failure (1.56 [1.45-1.69]), and non-fatal myocardial infarc-
tion (1.54 [1.42-1.67]). In BASCORE Study [31], in Spain,
type 2 diabetes was associated with greater complications
and mortality [Incidence rates (1,000 person-years)]: coron-
ary heart disease (21.6 [95 % CI 17.9-25.9]); Stroke (14.6
[11.7-18.1]) and peripheral arterial disease (12.3 [9.6, 15.5])
and Cañón Barroso L et al. [27] found that incidence of
stroke, coronary and global cardiovascular events in dia-
betic patients were 14.7 %, 9.3 % and 21.3 %, respectively.
When 45 prediction models were analysed, 12 of them
exclusive to DM2 patients and one third of them with
external validation, Van Dieren et al. indicated poor re-
sults. Furthermore, the discriminative capacity was mod-
erate, and its use in daily clinical practice had a low
impact on the final results [32].
Currently, FRAMINGHAM-REGICOR equation is rec-
ommended in Spain to estimate the coronary risk of the
DM2 population (Diabetes Strategy of the National Health
System 2012) [33]. The risk equations are the result of pro-
spective cohort studies, and all estimate the probability of
presenting a cardiovascular or coronary event in a deter-
mined time in the presence or absence of the CVRF. It is
likely that the DM2 specific population models can predict
a CVR better than the ones based on general populations
as the latter tend to underestimate the risk for diabetes
Table 5 Multivariate analysis of variables associated with disagreement among REGICOR (Framingham adapted to the Spanish
population), UKPDS, and ADVANCE functions
REGICOR vs.
UKPDS (OR; CI 95 %) ADVANCE (OR; CI 95 %)
Age centred (for year) 1.11 (1.08–1.15)* 1.42 (1.32–1.53)*
Gender (women) 0.23 (0.15–0.37)* 0.02 (0.008–0.05)*
Years since diabetes diagnosis
6–10 2.4 (1.38–4.15)** 189.2 (47.8–748.8)*
11–20 18.1 (10.2–32.1)* 10.7 × 103 (1.7 × 103–65.4 × 103)*
> 20 81.3 (22.2–297.6)* 2.06 × 105 (8.49 × 103–5.0 × 106)*
Non-HDL cholesterol (mg/dL) 1.012 (1.006–1.017)* 1.02 (1.01–1.03)*
HbA1c (for each 1 %) 1.39 (1.20–1.61)* 2.68 (2.03–3.52)*
Tobacco (yes) 1.41 (0.8–2.51) 2.6 (1.04–6.53)**
UAER (mg/gr) 0.999 (0.991–1.001) 1.01 (1.00–1.02)*
Pulse pressure (mmHg) 1.01 (0.99–1.03) 1.06 (1.03–1.09)*
Hypertension treatment (yes) 1.20 (0.75–1.92) 2.98 (1.37–6.45)**
Retinopathy (yes) 1.58 (0.81–3.09) 5.42 (1.83–16.0)**
0 = no disagreement, 1 = disagreement
Adjusted for ethnicity, body mass index, waist circumference, diabetes therapy and type, systolic blood pressure, diastolic blood pressure, dyslipidaemia therapy
and years since diabetes diagnosis
UAER: urinary albumin excretion rate
*p < 0.001
**p < 0.05
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mellitus patients [34]. The most important aspect of a risk
equation is the possibility of accurately stratifying high and
low risk [35]. In addition to classical CVRF, other factors
that affect the prognosis of a patient might be a family his-
tory of an early CVD, years of evolution of diabetes, high
levels of HbA1c, chronic kidney disease, diabetic retinop-
athy and atrial fibrillation [19]. Including these factors
would most likely improve the CVD stratification. Our
study identifies some variables associated with the dis-
agreement among the different equations in order to con-
sider the development of a new DM2 population-specific
risk equation: years of evolution of diabetes, pulse pressure,
waist circumference, presence of kidney disease or retinop-
athy and treatment with insulin or antihypertensives.
Among the limitations of this study, it should be consid-
ered that this was a cross-sectional study and that morbi-
mortality evolution data was not available to assess the
predictive capacity of each equation. Additionally, the
three cohorts included show great heterogeneity, which
has prevented a bivariate analysis. However, the results of
the global lineal models and the models performed identi-
cally for each cohort separately show the same results, val-
idating the global results for all three cohorts.
Conclusions
The practical implications of these results are evident. A
further study would be necessary to carry out a new car-
diovascular risk prediction model for DM2 in the Spanish
(southern Europe) population. This study should focus on
the validation and improvement of the performance of one
of these existing prediction models, more than on the de-
velopment of a new prediction model, adapting the existing
model to the Spanish population and adding new predict-
ive variables. This engine should be evaluated prospectively
in a contemporary cohort of diabetic patients to provide
more reliable risk estimations than the current models.
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